Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
Jonker JT, Wang Y, de Haan W, Diamant M, Rijzewijk LJ, van der Meer RW, Lamb HJ, Tamsma JT, de Roos A, Romijn JA, Rensen PC, Smit JW. Jonker JT, et al. Among authors: de roos a, de haan w. Diabetes Care. 2010 Jul;33(7):1625-8. doi: 10.2337/dc09-1935. Epub 2010 Feb 11. Diabetes Care. 2010. PMID: 20150294 Free PMC article. Clinical Trial.
Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, Rensen PC. de Vries-van der Weij J, et al. Among authors: de haan w. Endocrinology. 2009 May;150(5):2368-75. doi: 10.1210/en.2008-1540. Epub 2009 Jan 15. Endocrinology. 2009. PMID: 19147676 Clinical Trial.
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC. Westerterp M, et al. Among authors: de haan w. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2552-9. doi: 10.1161/01.ATV.0000243925.65265.3c. Epub 2006 Aug 31. Arterioscler Thromb Vasc Biol. 2006. PMID: 16946130 Free article.
Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.
Van Eck M, Ye D, Hildebrand RB, Kar Kruijt J, de Haan W, Hoekstra M, Rensen PC, Ehnholm C, Jauhiainen M, Van Berkel TJ. Van Eck M, et al. Among authors: de haan w. Circ Res. 2007 Mar 16;100(5):678-85. doi: 10.1161/01.RES.0000260202.79927.4f. Epub 2007 Feb 9. Circ Res. 2007. PMID: 17293475
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC. de Haan W, et al. Among authors: de vries van der weij j. Circulation. 2008 May 13;117(19):2515-22. doi: 10.1161/CIRCULATIONAHA.107.761965. Epub 2008 May 5. Circulation. 2008. PMID: 18458167
PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.
de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC. de Haan W, et al. Among authors: de vries van der weij j. Biochim Biophys Acta. 2009 Mar;1791(3):191-7. doi: 10.1016/j.bbalip.2008.12.008. Epub 2008 Dec 25. Biochim Biophys Acta. 2009. PMID: 19150509
91 results